nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP3A4—bone cancer	0.631	1	CbGaD
Methadone—CYP2B6—Cisplatin—bone cancer	0.0346	0.255	CbGbCtD
Methadone—CYP2B6—Doxorubicin—bone cancer	0.0232	0.171	CbGbCtD
Methadone—CYP2C9—Cisplatin—bone cancer	0.0183	0.135	CbGbCtD
Methadone—ABCB1—Cisplatin—bone cancer	0.0177	0.131	CbGbCtD
Methadone—Chronic hepatitis—Methotrexate—bone cancer	0.0131	0.116	CcSEcCtD
Methadone—ABCB1—Doxorubicin—bone cancer	0.0119	0.0877	CbGbCtD
Methadone—ABCB1—Methotrexate—bone cancer	0.0115	0.085	CbGbCtD
Methadone—CYP2D6—Doxorubicin—bone cancer	0.0112	0.0826	CbGbCtD
Methadone—CYP3A4—Doxorubicin—bone cancer	0.00711	0.0525	CbGbCtD
Methadone—Phlebitis—Carboplatin—bone cancer	0.00412	0.0366	CcSEcCtD
Methadone—Rhinorrhoea—Cisplatin—bone cancer	0.00177	0.0157	CcSEcCtD
Methadone—Pain—Carboplatin—bone cancer	0.00149	0.0133	CcSEcCtD
Methadone—Cardiomyopathy—Epirubicin—bone cancer	0.00144	0.0128	CcSEcCtD
Methadone—Osteoporosis—Methotrexate—bone cancer	0.0014	0.0125	CcSEcCtD
Methadone—Body temperature increased—Carboplatin—bone cancer	0.00138	0.0123	CcSEcCtD
Methadone—Multiple fractures—Methotrexate—bone cancer	0.00135	0.012	CcSEcCtD
Methadone—Fracture—Methotrexate—bone cancer	0.00135	0.012	CcSEcCtD
Methadone—Cardiomyopathy—Doxorubicin—bone cancer	0.00133	0.0118	CcSEcCtD
Methadone—Hypothermia—Epirubicin—bone cancer	0.00131	0.0117	CcSEcCtD
Methadone—Body temperature decreased—Epirubicin—bone cancer	0.00131	0.0117	CcSEcCtD
Methadone—Lacrimation—Epirubicin—bone cancer	0.00125	0.0111	CcSEcCtD
Methadone—Body temperature decreased—Doxorubicin—bone cancer	0.00122	0.0108	CcSEcCtD
Methadone—Hypothermia—Doxorubicin—bone cancer	0.00122	0.0108	CcSEcCtD
Methadone—Phlebitis—Cisplatin—bone cancer	0.00121	0.0107	CcSEcCtD
Methadone—Hypomagnesaemia—Epirubicin—bone cancer	0.00116	0.0103	CcSEcCtD
Methadone—Lacrimation—Doxorubicin—bone cancer	0.00116	0.0103	CcSEcCtD
Methadone—Lung disorder—Methotrexate—bone cancer	0.00111	0.00988	CcSEcCtD
Methadone—Redness—Epirubicin—bone cancer	0.00109	0.0097	CcSEcCtD
Methadone—Hypomagnesaemia—Doxorubicin—bone cancer	0.00107	0.00953	CcSEcCtD
Methadone—Lung disorder—Epirubicin—bone cancer	0.00104	0.00925	CcSEcCtD
Methadone—Redness—Doxorubicin—bone cancer	0.00101	0.00897	CcSEcCtD
Methadone—Irritability—Cisplatin—bone cancer	0.000994	0.00883	CcSEcCtD
Methadone—Lung disorder—Doxorubicin—bone cancer	0.000963	0.00856	CcSEcCtD
Methadone—Orthostatic hypotension—Cisplatin—bone cancer	0.000951	0.00845	CcSEcCtD
Methadone—Hypokalaemia—Cisplatin—bone cancer	0.000948	0.00842	CcSEcCtD
Methadone—Nasopharyngitis—Cisplatin—bone cancer	0.000931	0.00827	CcSEcCtD
Methadone—Sweating increased—Cisplatin—bone cancer	0.000877	0.00779	CcSEcCtD
Methadone—Glossitis—Methotrexate—bone cancer	0.000854	0.00759	CcSEcCtD
Methadone—Amenorrhoea—Epirubicin—bone cancer	0.000838	0.00745	CcSEcCtD
Methadone—Glossitis—Epirubicin—bone cancer	0.000799	0.0071	CcSEcCtD
Methadone—Lacrimation increased—Epirubicin—bone cancer	0.000799	0.0071	CcSEcCtD
Methadone—Amenorrhoea—Doxorubicin—bone cancer	0.000776	0.00689	CcSEcCtD
Methadone—Lacrimation increased—Doxorubicin—bone cancer	0.00074	0.00657	CcSEcCtD
Methadone—Glossitis—Doxorubicin—bone cancer	0.00074	0.00657	CcSEcCtD
Methadone—Ventricular tachycardia—Epirubicin—bone cancer	0.000737	0.00655	CcSEcCtD
Methadone—Bradycardia—Cisplatin—bone cancer	0.000733	0.00652	CcSEcCtD
Methadone—Dermatitis contact—Epirubicin—bone cancer	0.000728	0.00647	CcSEcCtD
Methadone—Pulmonary oedema—Methotrexate—bone cancer	0.000701	0.00623	CcSEcCtD
Methadone—Visual impairment—Cisplatin—bone cancer	0.000694	0.00617	CcSEcCtD
Methadone—Oxaprozin—PTGS2—bone cancer	0.000688	0.0959	CrCbGaD
Methadone—Ventricular tachycardia—Doxorubicin—bone cancer	0.000682	0.00606	CcSEcCtD
Methadone—Dermatitis contact—Doxorubicin—bone cancer	0.000674	0.00599	CcSEcCtD
Methadone—Flushing—Cisplatin—bone cancer	0.000669	0.00594	CcSEcCtD
Methadone—Pulmonary oedema—Epirubicin—bone cancer	0.000656	0.00583	CcSEcCtD
Methadone—Arrhythmia—Cisplatin—bone cancer	0.000644	0.00572	CcSEcCtD
Methadone—Erythema—Cisplatin—bone cancer	0.000627	0.00557	CcSEcCtD
Methadone—Phlebitis—Epirubicin—bone cancer	0.000621	0.00552	CcSEcCtD
Methadone—Pulmonary oedema—Doxorubicin—bone cancer	0.000607	0.00539	CcSEcCtD
Methadone—Visual disturbance—Methotrexate—bone cancer	0.000603	0.00536	CcSEcCtD
Methadone—Muscle spasms—Cisplatin—bone cancer	0.000603	0.00536	CcSEcCtD
Methadone—Tremor—Cisplatin—bone cancer	0.000588	0.00522	CcSEcCtD
Methadone—Alimemazine—CYP3A4—bone cancer	0.000578	0.0805	CrCbGaD
Methadone—Phlebitis—Doxorubicin—bone cancer	0.000574	0.0051	CcSEcCtD
Methadone—Darifenacin—CYP3A4—bone cancer	0.000553	0.0772	CrCbGaD
Methadone—Cardiac failure—Epirubicin—bone cancer	0.000548	0.00487	CcSEcCtD
Methadone—Irritability—Methotrexate—bone cancer	0.000545	0.00485	CcSEcCtD
Methadone—Convulsion—Cisplatin—bone cancer	0.000543	0.00483	CcSEcCtD
Methadone—Anxiety—Cisplatin—bone cancer	0.000532	0.00473	CcSEcCtD
Methadone—Anaphylactic shock—Cisplatin—bone cancer	0.000512	0.00455	CcSEcCtD
Methadone—Oedema—Cisplatin—bone cancer	0.000512	0.00455	CcSEcCtD
Methadone—Disopyramide—CYP3A4—bone cancer	0.00051	0.0711	CrCbGaD
Methadone—Cardiac arrest—Epirubicin—bone cancer	0.000508	0.00452	CcSEcCtD
Methadone—Cardiac failure—Doxorubicin—bone cancer	0.000507	0.0045	CcSEcCtD
Methadone—Thrombocytopenia—Cisplatin—bone cancer	0.000501	0.00445	CcSEcCtD
Methadone—Tachycardia—Cisplatin—bone cancer	0.000499	0.00444	CcSEcCtD
Methadone—Hyperhidrosis—Cisplatin—bone cancer	0.000495	0.0044	CcSEcCtD
Methadone—Orthostatic hypotension—Epirubicin—bone cancer	0.000488	0.00434	CcSEcCtD
Methadone—Anorexia—Cisplatin—bone cancer	0.000488	0.00433	CcSEcCtD
Methadone—Hypokalaemia—Epirubicin—bone cancer	0.000487	0.00432	CcSEcCtD
Methadone—Hypotension—Cisplatin—bone cancer	0.000478	0.00425	CcSEcCtD
Methadone—Nasopharyngitis—Epirubicin—bone cancer	0.000478	0.00425	CcSEcCtD
Methadone—Cardiac arrest—Doxorubicin—bone cancer	0.00047	0.00418	CcSEcCtD
Methadone—Phenylbutazone—CYP3A4—bone cancer	0.000464	0.0647	CrCbGaD
Methadone—Phenylbutazone—PTGS2—bone cancer	0.000454	0.0634	CrCbGaD
Methadone—Orthostatic hypotension—Doxorubicin—bone cancer	0.000452	0.00402	CcSEcCtD
Methadone—Hypokalaemia—Doxorubicin—bone cancer	0.00045	0.004	CcSEcCtD
Methadone—Decreased appetite—Cisplatin—bone cancer	0.000445	0.00395	CcSEcCtD
Methadone—Nasopharyngitis—Doxorubicin—bone cancer	0.000442	0.00393	CcSEcCtD
Methadone—Drowsiness—Methotrexate—bone cancer	0.00044	0.00391	CcSEcCtD
Methadone—Pain—Cisplatin—bone cancer	0.000438	0.00389	CcSEcCtD
Methadone—Sweating—Methotrexate—bone cancer	0.000422	0.00375	CcSEcCtD
Methadone—Feeling abnormal—Cisplatin—bone cancer	0.000422	0.00375	CcSEcCtD
Methadone—Weight increased—Epirubicin—bone cancer	0.000421	0.00374	CcSEcCtD
Methadone—Weight decreased—Epirubicin—bone cancer	0.000418	0.00372	CcSEcCtD
Methadone—Levomethadyl Acetate—CYP3A4—bone cancer	0.000416	0.058	CrCbGaD
Methadone—Clotrimazole—CYP3A4—bone cancer	0.000416	0.058	CrCbGaD
Methadone—Drowsiness—Epirubicin—bone cancer	0.000412	0.00366	CcSEcCtD
Methadone—Body temperature increased—Cisplatin—bone cancer	0.000405	0.00359	CcSEcCtD
Methadone—Sweating—Epirubicin—bone cancer	0.000395	0.00351	CcSEcCtD
Methadone—Weight increased—Doxorubicin—bone cancer	0.000389	0.00346	CcSEcCtD
Methadone—Weight decreased—Doxorubicin—bone cancer	0.000387	0.00344	CcSEcCtD
Methadone—Drowsiness—Doxorubicin—bone cancer	0.000381	0.00339	CcSEcCtD
Methadone—Visual impairment—Methotrexate—bone cancer	0.000381	0.00338	CcSEcCtD
Methadone—Hypersensitivity—Cisplatin—bone cancer	0.000377	0.00335	CcSEcCtD
Methadone—Bradycardia—Epirubicin—bone cancer	0.000377	0.00335	CcSEcCtD
Methadone—Asthenia—Cisplatin—bone cancer	0.000367	0.00326	CcSEcCtD
Methadone—Sweating—Doxorubicin—bone cancer	0.000366	0.00325	CcSEcCtD
Methadone—Modafinil—CYP3A4—bone cancer	0.000364	0.0507	CrCbGaD
Methadone—Dextropropoxyphene—CYP3A4—bone cancer	0.000359	0.0501	CrCbGaD
Methadone—Visual impairment—Epirubicin—bone cancer	0.000356	0.00317	CcSEcCtD
Methadone—Fentanyl—CYP3A4—bone cancer	0.000356	0.0496	CrCbGaD
Methadone—Chills—Methotrexate—bone cancer	0.000355	0.00315	CcSEcCtD
Methadone—Diarrhoea—Cisplatin—bone cancer	0.00035	0.00311	CcSEcCtD
Methadone—Bradycardia—Doxorubicin—bone cancer	0.000348	0.0031	CcSEcCtD
Methadone—Erythema—Methotrexate—bone cancer	0.000344	0.00306	CcSEcCtD
Methadone—Flushing—Epirubicin—bone cancer	0.000343	0.00305	CcSEcCtD
Methadone—Loperamide—CYP3A4—bone cancer	0.000343	0.0478	CrCbGaD
Methadone—Chills—Epirubicin—bone cancer	0.000332	0.00295	CcSEcCtD
Methadone—Arrhythmia—Epirubicin—bone cancer	0.00033	0.00294	CcSEcCtD
Methadone—Visual impairment—Doxorubicin—bone cancer	0.00033	0.00293	CcSEcCtD
Methadone—Vomiting—Cisplatin—bone cancer	0.000325	0.00289	CcSEcCtD
Methadone—Rash—Cisplatin—bone cancer	0.000323	0.00287	CcSEcCtD
Methadone—Dermatitis—Cisplatin—bone cancer	0.000322	0.00286	CcSEcCtD
Methadone—Erythema—Epirubicin—bone cancer	0.000322	0.00286	CcSEcCtD
Methadone—Flushing—Doxorubicin—bone cancer	0.000318	0.00282	CcSEcCtD
Methadone—Benzphetamine—CYP3A4—bone cancer	0.000315	0.044	CrCbGaD
Methadone—Atomoxetine—CYP3A4—bone cancer	0.000313	0.0436	CrCbGaD
Methadone—Muscle spasms—Epirubicin—bone cancer	0.00031	0.00275	CcSEcCtD
Methadone—Vertigo—Methotrexate—bone cancer	0.000309	0.00275	CcSEcCtD
Methadone—Chills—Doxorubicin—bone cancer	0.000307	0.00273	CcSEcCtD
Methadone—Arrhythmia—Doxorubicin—bone cancer	0.000306	0.00272	CcSEcCtD
Methadone—Nausea—Cisplatin—bone cancer	0.000304	0.0027	CcSEcCtD
Methadone—Phenoxybenzamine—CYP3A4—bone cancer	0.000301	0.042	CrCbGaD
Methadone—Convulsion—Methotrexate—bone cancer	0.000298	0.00265	CcSEcCtD
Methadone—Erythema—Doxorubicin—bone cancer	0.000298	0.00265	CcSEcCtD
Methadone—Agitation—Epirubicin—bone cancer	0.000296	0.00263	CcSEcCtD
Methadone—Vertigo—Epirubicin—bone cancer	0.000289	0.00257	CcSEcCtD
Methadone—Syncope—Epirubicin—bone cancer	0.000289	0.00257	CcSEcCtD
Methadone—Muscle spasms—Doxorubicin—bone cancer	0.000286	0.00255	CcSEcCtD
Methadone—Palpitations—Epirubicin—bone cancer	0.000285	0.00253	CcSEcCtD
Methadone—Confusional state—Methotrexate—bone cancer	0.000283	0.00252	CcSEcCtD
Methadone—Loss of consciousness—Epirubicin—bone cancer	0.000283	0.00251	CcSEcCtD
Methadone—Anaphylactic shock—Methotrexate—bone cancer	0.000281	0.0025	CcSEcCtD
Methadone—Convulsion—Epirubicin—bone cancer	0.000279	0.00248	CcSEcCtD
Methadone—Thrombocytopenia—Methotrexate—bone cancer	0.000275	0.00244	CcSEcCtD
Methadone—Agitation—Doxorubicin—bone cancer	0.000274	0.00243	CcSEcCtD
Methadone—Anxiety—Epirubicin—bone cancer	0.000273	0.00243	CcSEcCtD
Methadone—Hyperhidrosis—Methotrexate—bone cancer	0.000271	0.00241	CcSEcCtD
Methadone—Dry mouth—Epirubicin—bone cancer	0.000268	0.00238	CcSEcCtD
Methadone—Vertigo—Doxorubicin—bone cancer	0.000268	0.00238	CcSEcCtD
Methadone—Anorexia—Methotrexate—bone cancer	0.000268	0.00238	CcSEcCtD
Methadone—Syncope—Doxorubicin—bone cancer	0.000267	0.00237	CcSEcCtD
Methadone—Confusional state—Epirubicin—bone cancer	0.000265	0.00235	CcSEcCtD
Methadone—Palpitations—Doxorubicin—bone cancer	0.000263	0.00234	CcSEcCtD
Methadone—Oedema—Epirubicin—bone cancer	0.000263	0.00234	CcSEcCtD
Methadone—Anaphylactic shock—Epirubicin—bone cancer	0.000263	0.00234	CcSEcCtD
Methadone—Hypotension—Methotrexate—bone cancer	0.000262	0.00233	CcSEcCtD
Methadone—Loss of consciousness—Doxorubicin—bone cancer	0.000262	0.00233	CcSEcCtD
Methadone—Shock—Epirubicin—bone cancer	0.000259	0.0023	CcSEcCtD
Methadone—Convulsion—Doxorubicin—bone cancer	0.000258	0.00229	CcSEcCtD
Methadone—Thrombocytopenia—Epirubicin—bone cancer	0.000257	0.00229	CcSEcCtD
Methadone—Trimipramine—CYP3A4—bone cancer	0.000257	0.0359	CrCbGaD
Methadone—Tachycardia—Epirubicin—bone cancer	0.000257	0.00228	CcSEcCtD
Methadone—Hyperhidrosis—Epirubicin—bone cancer	0.000254	0.00226	CcSEcCtD
Methadone—Insomnia—Methotrexate—bone cancer	0.000254	0.00226	CcSEcCtD
Methadone—Anxiety—Doxorubicin—bone cancer	0.000253	0.00225	CcSEcCtD
Methadone—Anorexia—Epirubicin—bone cancer	0.000251	0.00223	CcSEcCtD
Methadone—Somnolence—Methotrexate—bone cancer	0.00025	0.00222	CcSEcCtD
Methadone—Dry mouth—Doxorubicin—bone cancer	0.000248	0.0022	CcSEcCtD
Methadone—Tamoxifen—CYP3A4—bone cancer	0.000246	0.0343	CrCbGaD
Methadone—Hypotension—Epirubicin—bone cancer	0.000246	0.00218	CcSEcCtD
Methadone—Confusional state—Doxorubicin—bone cancer	0.000245	0.00218	CcSEcCtD
Methadone—Decreased appetite—Methotrexate—bone cancer	0.000244	0.00217	CcSEcCtD
Methadone—Anaphylactic shock—Doxorubicin—bone cancer	0.000243	0.00216	CcSEcCtD
Methadone—Oedema—Doxorubicin—bone cancer	0.000243	0.00216	CcSEcCtD
Methadone—Pain—Methotrexate—bone cancer	0.00024	0.00213	CcSEcCtD
Methadone—Shock—Doxorubicin—bone cancer	0.000239	0.00213	CcSEcCtD
Methadone—Orphenadrine—CYP3A4—bone cancer	0.000239	0.0333	CrCbGaD
Methadone—Thrombocytopenia—Doxorubicin—bone cancer	0.000238	0.00212	CcSEcCtD
Methadone—Insomnia—Epirubicin—bone cancer	0.000238	0.00211	CcSEcCtD
Methadone—Tachycardia—Doxorubicin—bone cancer	0.000237	0.00211	CcSEcCtD
Methadone—Hyperhidrosis—Doxorubicin—bone cancer	0.000235	0.00209	CcSEcCtD
Methadone—Somnolence—Epirubicin—bone cancer	0.000234	0.00208	CcSEcCtD
Methadone—Anorexia—Doxorubicin—bone cancer	0.000232	0.00206	CcSEcCtD
Methadone—Feeling abnormal—Methotrexate—bone cancer	0.000231	0.00206	CcSEcCtD
Methadone—Gastrointestinal pain—Methotrexate—bone cancer	0.00023	0.00204	CcSEcCtD
Methadone—Decreased appetite—Epirubicin—bone cancer	0.000228	0.00203	CcSEcCtD
Methadone—Hypotension—Doxorubicin—bone cancer	0.000227	0.00202	CcSEcCtD
Methadone—Pain—Epirubicin—bone cancer	0.000225	0.002	CcSEcCtD
Methadone—Constipation—Epirubicin—bone cancer	0.000225	0.002	CcSEcCtD
Methadone—Urticaria—Methotrexate—bone cancer	0.000223	0.00198	CcSEcCtD
Methadone—Body temperature increased—Methotrexate—bone cancer	0.000222	0.00197	CcSEcCtD
Methadone—Abdominal pain—Methotrexate—bone cancer	0.000222	0.00197	CcSEcCtD
Methadone—Insomnia—Doxorubicin—bone cancer	0.00022	0.00195	CcSEcCtD
Methadone—Feeling abnormal—Epirubicin—bone cancer	0.000217	0.00192	CcSEcCtD
Methadone—Somnolence—Doxorubicin—bone cancer	0.000216	0.00192	CcSEcCtD
Methadone—Gastrointestinal pain—Epirubicin—bone cancer	0.000215	0.00191	CcSEcCtD
Methadone—Decreased appetite—Doxorubicin—bone cancer	0.000211	0.00188	CcSEcCtD
Methadone—Urticaria—Epirubicin—bone cancer	0.000209	0.00186	CcSEcCtD
Methadone—Pain—Doxorubicin—bone cancer	0.000208	0.00185	CcSEcCtD
Methadone—Constipation—Doxorubicin—bone cancer	0.000208	0.00185	CcSEcCtD
Methadone—Body temperature increased—Epirubicin—bone cancer	0.000208	0.00185	CcSEcCtD
Methadone—Abdominal pain—Epirubicin—bone cancer	0.000208	0.00185	CcSEcCtD
Methadone—Hypersensitivity—Methotrexate—bone cancer	0.000207	0.00184	CcSEcCtD
Methadone—Asthenia—Methotrexate—bone cancer	0.000201	0.00179	CcSEcCtD
Methadone—Feeling abnormal—Doxorubicin—bone cancer	0.0002	0.00178	CcSEcCtD
Methadone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000199	0.00177	CcSEcCtD
Methadone—Pruritus—Methotrexate—bone cancer	0.000199	0.00177	CcSEcCtD
Methadone—Hypersensitivity—Epirubicin—bone cancer	0.000194	0.00172	CcSEcCtD
Methadone—Urticaria—Doxorubicin—bone cancer	0.000193	0.00172	CcSEcCtD
Methadone—Abdominal pain—Doxorubicin—bone cancer	0.000192	0.00171	CcSEcCtD
Methadone—Body temperature increased—Doxorubicin—bone cancer	0.000192	0.00171	CcSEcCtD
Methadone—Diarrhoea—Methotrexate—bone cancer	0.000192	0.00171	CcSEcCtD
Methadone—Asthenia—Epirubicin—bone cancer	0.000189	0.00168	CcSEcCtD
Methadone—Pruritus—Epirubicin—bone cancer	0.000186	0.00165	CcSEcCtD
Methadone—Dizziness—Methotrexate—bone cancer	0.000186	0.00165	CcSEcCtD
Methadone—Diarrhoea—Epirubicin—bone cancer	0.00018	0.0016	CcSEcCtD
Methadone—Hypersensitivity—Doxorubicin—bone cancer	0.000179	0.00159	CcSEcCtD
Methadone—Vomiting—Methotrexate—bone cancer	0.000179	0.00159	CcSEcCtD
Methadone—OPRD1—GPCR downstream signaling—GRM4—bone cancer	0.000178	0.00157	CbGpPWpGaD
Methadone—Rash—Methotrexate—bone cancer	0.000177	0.00157	CcSEcCtD
Methadone—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000177	0.00155	CbGpPWpGaD
Methadone—Dermatitis—Methotrexate—bone cancer	0.000177	0.00157	CcSEcCtD
Methadone—Headache—Methotrexate—bone cancer	0.000176	0.00156	CcSEcCtD
Methadone—Asthenia—Doxorubicin—bone cancer	0.000174	0.00155	CcSEcCtD
Methadone—Dizziness—Epirubicin—bone cancer	0.000174	0.00154	CcSEcCtD
Methadone—Pruritus—Doxorubicin—bone cancer	0.000172	0.00153	CcSEcCtD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000171	0.0015	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—SMO—bone cancer	0.000169	0.00148	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—JUN—bone cancer	0.000168	0.00148	CbGpPWpGaD
Methadone—Vomiting—Epirubicin—bone cancer	0.000167	0.00148	CcSEcCtD
Methadone—Nausea—Methotrexate—bone cancer	0.000167	0.00148	CcSEcCtD
Methadone—Diarrhoea—Doxorubicin—bone cancer	0.000166	0.00148	CcSEcCtD
Methadone—Rash—Epirubicin—bone cancer	0.000166	0.00147	CcSEcCtD
Methadone—Dermatitis—Epirubicin—bone cancer	0.000166	0.00147	CcSEcCtD
Methadone—Headache—Epirubicin—bone cancer	0.000165	0.00146	CcSEcCtD
Methadone—OPRD1—Signaling by GPCR—GRM4—bone cancer	0.000162	0.00142	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—RGS1—bone cancer	0.000162	0.00142	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—NT5C3A—bone cancer	0.000161	0.00142	CbGpPWpGaD
Methadone—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000161	0.00141	CbGpPWpGaD
Methadone—Dizziness—Doxorubicin—bone cancer	0.000161	0.00143	CcSEcCtD
Methadone—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.00016	0.0014	CbGpPWpGaD
Methadone—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000157	0.00138	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—GRM4—bone cancer	0.000156	0.00137	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—RGS1—bone cancer	0.000156	0.00137	CbGpPWpGaD
Methadone—Nausea—Epirubicin—bone cancer	0.000156	0.00139	CcSEcCtD
Methadone—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000156	0.00137	CbGpPWpGaD
Methadone—Vomiting—Doxorubicin—bone cancer	0.000155	0.00137	CcSEcCtD
Methadone—OPRD1—GPCR downstream signaling—GRM1—bone cancer	0.000155	0.00136	CbGpPWpGaD
Methadone—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000154	0.00135	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000154	0.00135	CbGpPWpGaD
Methadone—Rash—Doxorubicin—bone cancer	0.000153	0.00136	CcSEcCtD
Methadone—Dermatitis—Doxorubicin—bone cancer	0.000153	0.00136	CcSEcCtD
Methadone—Headache—Doxorubicin—bone cancer	0.000152	0.00135	CcSEcCtD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000151	0.00133	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—NDUFA12—bone cancer	0.000149	0.00131	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000149	0.00131	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000146	0.00128	CbGpPWpGaD
Methadone—Nausea—Doxorubicin—bone cancer	0.000144	0.00128	CcSEcCtD
Methadone—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000144	0.00126	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—SMO—bone cancer	0.000143	0.00125	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—GRM4—bone cancer	0.000142	0.00125	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—RGS1—bone cancer	0.000142	0.00125	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—GRM1—bone cancer	0.00014	0.00123	CbGpPWpGaD
Methadone—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000137	0.00121	CbGpPWpGaD
Methadone—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000137	0.0012	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—GRM1—bone cancer	0.000135	0.00119	CbGpPWpGaD
Methadone—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000135	0.00119	CbGpPWpGaD
Methadone—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000135	0.00118	CbGpPWpGaD
Methadone—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000133	0.00117	CbGpPWpGaD
Methadone—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000133	0.00117	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—RGS1—bone cancer	0.000132	0.00116	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—GRM4—bone cancer	0.000132	0.00116	CbGpPWpGaD
Methadone—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000132	0.00116	CbGpPWpGaD
Methadone—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000131	0.00115	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000131	0.00115	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000129	0.00114	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000127	0.00111	CbGpPWpGaD
Methadone—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000124	0.00109	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—NT5C3A—bone cancer	0.000123	0.00108	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—GRM1—bone cancer	0.000123	0.00108	CbGpPWpGaD
Methadone—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000121	0.00106	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—RGS1—bone cancer	0.00012	0.00105	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—GRM4—bone cancer	0.00012	0.00105	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00012	0.00105	CbGpPWpGaD
Methadone—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000119	0.00104	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000119	0.00104	CbGpPWpGaD
Methadone—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000116	0.00102	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—GRM1—bone cancer	0.000115	0.00101	CbGpPWpGaD
Methadone—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000114	0.001	CbGpPWpGaD
Methadone—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000112	0.000983	CbGpPWpGaD
Methadone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000111	0.000974	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00011	0.000968	CbGpPWpGaD
Methadone—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.00011	0.000966	CbGpPWpGaD
Methadone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000109	0.000961	CbGpPWpGaD
Methadone—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000108	0.000953	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000108	0.000951	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000108	0.000947	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000107	0.000942	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000107	0.000938	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—GRM1—bone cancer	0.000104	0.000913	CbGpPWpGaD
Methadone—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000103	0.000906	CbGpPWpGaD
Methadone—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000102	0.000894	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000101	0.000889	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—GNA11—bone cancer	9.96e-05	0.000875	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—SMO—bone cancer	9.89e-05	0.000868	CbGpPWpGaD
Methadone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.58e-05	0.000841	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NDUFA12—bone cancer	9.57e-05	0.00084	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—GRM4—bone cancer	9.56e-05	0.00084	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RGS1—bone cancer	9.56e-05	0.00084	CbGpPWpGaD
Methadone—CYP2D6—Biological oxidations—GSTP1—bone cancer	9.49e-05	0.000833	CbGpPWpGaD
Methadone—CYP2C9—Biological oxidations—GSTP1—bone cancer	9.41e-05	0.000826	CbGpPWpGaD
Methadone—CYP1A2—Biological oxidations—CYP3A4—bone cancer	9.4e-05	0.000825	CbGpPWpGaD
Methadone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	9.36e-05	0.000822	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NDUFA12—bone cancer	9.35e-05	0.000821	CbGpPWpGaD
Methadone—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	9.28e-05	0.000815	CbGpPWpGaD
Methadone—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	9.27e-05	0.000814	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.05e-05	0.000795	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—GNA11—bone cancer	9.04e-05	0.000794	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—IL3—bone cancer	9.03e-05	0.000793	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.03e-05	0.000793	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—GNA11—bone cancer	8.73e-05	0.000767	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—SMO—bone cancer	8.67e-05	0.000761	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	8.66e-05	0.000761	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.48e-05	0.000745	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.48e-05	0.000745	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—GRM4—bone cancer	8.38e-05	0.000736	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RGS1—bone cancer	8.38e-05	0.000736	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—GRM1—bone cancer	8.29e-05	0.000728	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL3—bone cancer	8.2e-05	0.00072	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NDUFA12—bone cancer	8.1e-05	0.000711	CbGpPWpGaD
Methadone—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.04e-05	0.000706	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—GNA11—bone cancer	7.93e-05	0.000696	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NT5C3A—bone cancer	7.93e-05	0.000696	CbGpPWpGaD
Methadone—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.93e-05	0.000696	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—IL3—bone cancer	7.92e-05	0.000695	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.79e-05	0.000684	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NT5C3A—bone cancer	7.75e-05	0.000681	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—GNA11—bone cancer	7.38e-05	0.000648	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—SMO—bone cancer	7.33e-05	0.000643	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	7.27e-05	0.000639	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—GRM1—bone cancer	7.27e-05	0.000638	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NDUFA12—bone cancer	7.23e-05	0.000635	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL3—bone cancer	7.19e-05	0.000631	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—GRM4—bone cancer	7.08e-05	0.000622	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RGS1—bone cancer	7.08e-05	0.000622	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—ENO2—bone cancer	7.06e-05	0.00062	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NDUFA12—bone cancer	7.06e-05	0.00062	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.71e-05	0.00059	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NT5C3A—bone cancer	6.71e-05	0.00059	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—GNA11—bone cancer	6.7e-05	0.000589	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—IL3—bone cancer	6.69e-05	0.000588	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NDUFA12—bone cancer	6.65e-05	0.000584	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NDUFA12—bone cancer	6.59e-05	0.000579	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—DHFR—bone cancer	6.55e-05	0.000576	CbGpPWpGaD
Methadone—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.2e-05	0.000545	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—GRM1—bone cancer	6.14e-05	0.00054	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—GNA11—bone cancer	6.12e-05	0.000538	CbGpPWpGaD
Methadone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.12e-05	0.000537	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL3—bone cancer	6.07e-05	0.000534	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NT5C3A—bone cancer	5.99e-05	0.000526	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NT5C3A—bone cancer	5.85e-05	0.000514	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SMO—bone cancer	5.84e-05	0.000513	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NDUFA12—bone cancer	5.63e-05	0.000495	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—CYP3A4—bone cancer	5.55e-05	0.000488	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NT5C3A—bone cancer	5.51e-05	0.000484	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NT5C3A—bone cancer	5.46e-05	0.00048	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—ENO2—bone cancer	5.41e-05	0.000475	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—GNA11—bone cancer	5.34e-05	0.000469	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SMO—bone cancer	5.12e-05	0.00045	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—DHFR—bone cancer	5.02e-05	0.000441	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.98e-05	0.000437	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ATF1—bone cancer	4.97e-05	0.000436	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL3—bone cancer	4.84e-05	0.000425	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.8e-05	0.000421	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—GSTP1—bone cancer	4.75e-05	0.000417	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ENO2—bone cancer	4.7e-05	0.000412	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—GNA11—bone cancer	4.69e-05	0.000412	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—GNA11—bone cancer	4.68e-05	0.000411	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NT5C3A—bone cancer	4.67e-05	0.00041	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—DHFR—bone cancer	4.36e-05	0.000383	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ATF1—bone cancer	4.35e-05	0.000382	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NDUFA12—bone cancer	4.35e-05	0.000382	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SMO—bone cancer	4.33e-05	0.00038	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.33e-05	0.00038	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CYP3A4—bone cancer	4.25e-05	0.000373	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL3—bone cancer	4.25e-05	0.000373	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.23e-05	0.000371	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TGFBR2—bone cancer	4.14e-05	0.000364	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GNA11—bone cancer	4.07e-05	0.000358	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—GNA11—bone cancer	3.96e-05	0.000348	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IGF1R—bone cancer	3.9e-05	0.000342	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CYP3A4—bone cancer	3.69e-05	0.000324	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ATF1—bone cancer	3.68e-05	0.000323	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—GSTP1—bone cancer	3.64e-05	0.000319	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TGFBR2—bone cancer	3.63e-05	0.000319	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NT5C3A—bone cancer	3.6e-05	0.000316	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL3—bone cancer	3.59e-05	0.000315	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ENO2—bone cancer	3.47e-05	0.000305	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IGF1R—bone cancer	3.42e-05	0.0003	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.4e-05	0.000299	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ENO2—bone cancer	3.39e-05	0.000298	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—DHFR—bone cancer	3.22e-05	0.000283	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GSTP1—bone cancer	3.16e-05	0.000277	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—DHFR—bone cancer	3.15e-05	0.000277	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TGFBR2—bone cancer	3.07e-05	0.00027	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GNA11—bone cancer	3.01e-05	0.000264	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GNA11—bone cancer	2.94e-05	0.000258	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ENO2—bone cancer	2.94e-05	0.000258	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IGF1R—bone cancer	2.89e-05	0.000254	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.86e-05	0.000251	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KIT—bone cancer	2.83e-05	0.000248	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CYP3A4—bone cancer	2.73e-05	0.00024	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—DHFR—bone cancer	2.73e-05	0.00024	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CYP3A4—bone cancer	2.67e-05	0.000234	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—BRAF—bone cancer	2.66e-05	0.000233	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ENO2—bone cancer	2.62e-05	0.00023	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—EGFR—bone cancer	2.57e-05	0.000226	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ENO2—bone cancer	2.56e-05	0.000225	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GNA11—bone cancer	2.55e-05	0.000224	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KIT—bone cancer	2.48e-05	0.000218	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTGS2—bone cancer	2.46e-05	0.000216	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—DHFR—bone cancer	2.43e-05	0.000214	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ENO2—bone cancer	2.41e-05	0.000212	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ENO2—bone cancer	2.39e-05	0.00021	CbGpPWpGaD
Methadone—ABCB1—Metabolism—DHFR—bone cancer	2.38e-05	0.000209	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GSTP1—bone cancer	2.33e-05	0.000205	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—BRAF—bone cancer	2.33e-05	0.000205	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CYP3A4—bone cancer	2.31e-05	0.000203	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.3e-05	0.000202	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GSTP1—bone cancer	2.28e-05	0.0002	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GNA11—bone cancer	2.28e-05	0.0002	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—bone cancer	2.26e-05	0.000198	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—DHFR—bone cancer	2.24e-05	0.000197	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MDM2—bone cancer	2.23e-05	0.000195	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GNA11—bone cancer	2.22e-05	0.000195	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—DHFR—bone cancer	2.22e-05	0.000195	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KIT—bone cancer	2.09e-05	0.000184	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GNA11—bone cancer	2.09e-05	0.000184	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GNA11—bone cancer	2.07e-05	0.000182	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CYP3A4—bone cancer	2.06e-05	0.000181	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.05e-05	0.00018	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ENO2—bone cancer	2.04e-05	0.00018	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CYP3A4—bone cancer	2.01e-05	0.000177	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GSTP1—bone cancer	1.98e-05	0.000174	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—BRAF—bone cancer	1.97e-05	0.000173	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MDM2—bone cancer	1.95e-05	0.000171	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—JUN—bone cancer	1.93e-05	0.00017	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—bone cancer	1.91e-05	0.000168	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.9e-05	0.000167	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—DHFR—bone cancer	1.9e-05	0.000167	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—bone cancer	1.88e-05	0.000165	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—bone cancer	1.88e-05	0.000165	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000165	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.87e-05	0.000164	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GNA11—bone cancer	1.77e-05	0.000156	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTP1—bone cancer	1.76e-05	0.000155	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTP1—bone cancer	1.72e-05	0.000151	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—JUN—bone cancer	1.7e-05	0.000149	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—bone cancer	1.65e-05	0.000145	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MDM2—bone cancer	1.65e-05	0.000145	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—bone cancer	1.64e-05	0.000144	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTP1—bone cancer	1.62e-05	0.000143	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTP1—bone cancer	1.61e-05	0.000141	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CYP3A4—bone cancer	1.61e-05	0.000141	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.6e-05	0.00014	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ENO2—bone cancer	1.58e-05	0.000139	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—bone cancer	1.52e-05	0.000134	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—DHFR—bone cancer	1.46e-05	0.000129	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—JUN—bone cancer	1.43e-05	0.000126	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—bone cancer	1.39e-05	0.000123	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTP1—bone cancer	1.37e-05	0.000121	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GNA11—bone cancer	1.37e-05	0.00012	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—bone cancer	1.33e-05	0.000117	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—bone cancer	1.28e-05	0.000112	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—bone cancer	1.21e-05	0.000106	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—bone cancer	1.18e-05	0.000104	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—bone cancer	1.13e-05	9.9e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—bone cancer	1.12e-05	9.84e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTP1—bone cancer	1.06e-05	9.32e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—bone cancer	1.02e-05	8.99e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—bone cancer	9.46e-06	8.31e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—bone cancer	9.14e-06	8.03e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—bone cancer	8.92e-06	7.84e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—bone cancer	8.41e-06	7.38e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—bone cancer	8.33e-06	7.32e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—bone cancer	7.12e-06	6.25e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—bone cancer	5.5e-06	4.83e-05	CbGpPWpGaD
